In a study on 53 breast/ovarian cancer families, we previously identified three common deleterious founder mutations, 3450del4 and A1708E in BRCA1, and 3034del4 in BRCA2 (BIC nomenclature (https://research.nhgri.nih.gov/bic/)11. This evidence concerns the gene BRCA1 and ovarian cancer.